DNAY / Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announce more_horizontal

Codex DNA, Inc. (NASDAQ:DNAY ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Richard Lepke - Director, Investor Relati more_horizontal

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced more_horizontal

Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q4 2021 Results - Earnings Call Transcript more_horizontal

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announc more_horizontal

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announc more_horizontal

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announc more_horizontal

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announc more_horizontal